Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.

PloS one - 1 Jan 2018

Herbener Peter, Schönfeld Kurt, König Martin, Germer Matthias, Przyborski Jude M, Bernöster Katrin, Schüttrumpf Jörg

Abstract excerpt

An increasing number of monoclonal antibodies and derivatives such as antibody-drug conjugates (ADC) are of the IgG1 and IgG4 isotype with distinct structural and functional properties. In cases where antibody-mediated cytotoxicity is not desired, IgG4 is often used, as its Fc region is relatively poor at inducing antibody-dependent cell-mediated or complement-dependent cytotoxicity. IgG4 ADCs with highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens

Share to Cell Survival

Share to Dose-Response Relationship, Drug

Share to Immunoconjugates

Share to Immunoglobulin G

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29672587
DOI: 10.1371/journal.pone.0195823
PMCID: PMC5908158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.PMID 29672587Read ↗

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cellsSemantic proximity Read ↗

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivoSemantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read ↗

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodiesSemantic proximity Read ↗

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read ↗

Antibody Isotypes for Tumor ImmunotherapySemantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.Semantic proximity Read ↗

Preclinical evaluation of an antibody-based companion diagnostic for CD44v6 expressing cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.